Certified Advisory Corp Buys 40 Shares of Danaher Co. (NYSE:DHR)

Certified Advisory Corp boosted its stake in Danaher Co. (NYSE:DHR) by 4.5% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 926 shares of the conglomerate’s stock after buying an additional 40 shares during the quarter. Certified Advisory Corp’s holdings in Danaher were worth $231,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. DRW Securities LLC bought a new position in shares of Danaher during the second quarter valued at about $385,000. EverSource Wealth Advisors LLC increased its stake in Danaher by 12.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,531 shares of the conglomerate’s stock valued at $424,000 after buying an additional 165 shares during the last quarter. Fairscale Capital LLC bought a new position in shares of Danaher during the 2nd quarter worth approximately $340,000. Itau Unibanco Holding S.A. purchased a new position in shares of Danaher in the 2nd quarter worth approximately $67,000. Finally, Mount Yale Investment Advisors LLC grew its holdings in shares of Danaher by 43.8% in the second quarter. Mount Yale Investment Advisors LLC now owns 2,641 shares of the conglomerate’s stock valued at $660,000 after acquiring an additional 805 shares in the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Danaher

In other news, CFO Matthew Mcgrew sold 16,172 shares of the stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total value of $4,525,572.48. Following the transaction, the chief financial officer now owns 29,407 shares of the company’s stock, valued at approximately $8,229,254.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, SVP Brian W. Ellis sold 9,600 shares of the stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the transaction, the senior vice president now owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Matthew Mcgrew sold 16,172 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the sale, the chief financial officer now owns 29,407 shares of the company’s stock, valued at $8,229,254.88. The disclosure for this sale can be found here. Over the last quarter, insiders sold 39,659 shares of company stock valued at $11,042,433. Company insiders own 11.10% of the company’s stock.

Danaher Stock Up 0.2 %

DHR stock opened at $273.19 on Tuesday. The stock has a 50-day simple moving average of $268.16 and a two-hundred day simple moving average of $257.32. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $281.70. The firm has a market capitalization of $202.35 billion, a PE ratio of 46.30, a PEG ratio of 4.48 and a beta of 0.83. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, beating the consensus estimate of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same quarter in the previous year, the company earned $2.05 earnings per share. Danaher’s revenue for the quarter was down 2.9% on a year-over-year basis. On average, equities analysts predict that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be given a $0.27 dividend. The ex-dividend date of this dividend is Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.40%. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Analyst Upgrades and Downgrades

Several research firms have weighed in on DHR. Stifel Nicolaus boosted their price objective on Danaher from $235.00 to $250.00 and gave the stock a “hold” rating in a research report on Wednesday, July 24th. The Goldman Sachs Group lifted their price objective on shares of Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 24th. Evercore ISI reduced their target price on shares of Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a research report on Tuesday, July 2nd. Robert W. Baird lifted their price target on shares of Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a report on Wednesday, July 24th. Finally, Leerink Partners increased their price objective on Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. Seven research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat, Danaher has a consensus rating of “Moderate Buy” and an average price target of $278.94.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.